COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Treating Alzheimer's and Dementia With D-ribose

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02260141
Recruitment Status : Terminated (unable to get adequate enrollment)
First Posted : October 9, 2014
Last Update Posted : May 8, 2020
Information provided by (Responsible Party):
Practitioners Alliance Network

Brief Summary:
To study the effectiveness of d-ribose in treating Alzheimer's and Dementia

Condition or disease Intervention/treatment Phase
Alzheimers Dementia Dietary Supplement: d-ribose Not Applicable

Detailed Description:
Clinical experience and the pathophysiology of Alzheimer's, including neuronal insulin resistance, suggests that ribose improves clinical outcomes. This study will add ribose 5 gm 3 X day for 8 weeks to monitor outcomes in a pilot study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 3 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Single arm pilot study using ribose for alzheimers
Masking: None (Open Label)
Primary Purpose: Treatment
Actual Study Start Date : September 2014
Actual Primary Completion Date : October 2017
Actual Study Completion Date : October 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Dementia

Arm Intervention/treatment
Experimental: Treatment with d-ribose
Treatment with ribose 5 gm TID
Dietary Supplement: d-ribose
giving ribose in those with a diagnosis of Alzheimer's and/or dementia

Primary Outcome Measures :
  1. ADAS-ADL [ Time Frame: 2 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • A diagnosis of Alzheimer's and/or dementia with a Mini Mental Status Exam ( MMSE) score over 12 or being ambulatory and able to travel outside the home with assistance.
  • Must have a caregiver living with them.

Exclusion Criteria:

  • Overt and severe causes of secondary dementia such as metastatic brain cancers, or severe overt infectious encephalopathies or severe autoimmune illness.
  • Also, severe life threatening illnesses which would make them unlikely to be alive after 6-12 months.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02260141

Layout table for location information
United States, Hawaii
Kailua, Hawaii, United States, 96740
Sponsors and Collaborators
Practitioners Alliance Network
Layout table for additonal information
Responsible Party: Practitioners Alliance Network Identifier: NCT02260141    
Other Study ID Numbers: PAN- ALZ001
First Posted: October 9, 2014    Key Record Dates
Last Update Posted: May 8, 2020
Last Verified: October 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurocognitive Disorders
Mental Disorders